Merck shares have dropped by around a third since the start of July 2024, amid investor worries over how the company will ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

Merck has partnered with company builder mantro GmbH to launch EdiMembre, a deep-tech spinout that will commercialize Merck's ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

Tata Electronics is in discussions with Merck for an exclusive long-term agreement, potentially securing a primary supplier ...